sufentanil ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
opioid receptor agonists, analgesics, fentanyl derivatives 2491 56030-54-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • sulfentanyl
  • sulfentanil
  • sulfentanil citrate
  • sufentanil
  • sufentanil citrate
An opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent.
  • Molecular weight: 386.55
  • Formula: C22H30N2O2S
  • CLOGP: 3.59
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 32.78
  • ALOGS: -4.51
  • ROTB: 8

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 6 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.06 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 9.40 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 15 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.08 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 14 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 25, 2018 EMA LABORATOIRE AGUETTANT
May 4, 1984 FDA AKORN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 1777.17 29.56 430 6640 23203 63458749
Hypotension 326.01 29.56 257 6813 272347 63209605
Bronchospasm 270.17 29.56 93 6977 17187 63464765
Anaphylactic reaction 231.68 29.56 123 6947 65977 63415975
Maternal exposure during delivery 179.42 29.56 40 7030 1460 63480492
Exposure during pregnancy 156.38 29.56 133 6937 155414 63326538
Cardiac arrest 142.72 29.56 102 6968 92443 63389509
Anaphylactoid shock 111.94 29.56 21 7049 316 63481636
Circulatory collapse 106.58 29.56 51 7019 21887 63460065
Tachycardia 106.44 29.56 95 6975 118061 63363891
Type I hypersensitivity 105.90 29.56 30 7040 2912 63479040
Acute generalised exanthematous pustulosis 100.42 29.56 40 7030 11059 63470893
Allergy test negative 95.55 29.56 17 7053 187 63481765
Cardio-respiratory arrest 92.13 29.56 66 7004 59893 63422059
Mixed liver injury 87.80 29.56 29 7041 4706 63477246
Shock 85.82 29.56 45 7025 23418 63458534
Respiratory depression 76.22 29.56 35 7035 13680 63468272
Oliguria 76.12 29.56 31 7039 9070 63472882
Eosinophilia 75.77 29.56 41 7029 22715 63459237
Multiple organ dysfunction syndrome 74.87 29.56 57 7013 56695 63425257
Bradycardia 74.18 29.56 63 7007 73164 63408788
Fatigue 71.36 29.56 8 7062 888020 62593932
Hepatocellular injury 71.32 29.56 42 7028 27339 63454613
Drug reaction with eosinophilia and systemic symptoms 70.50 29.56 45 7025 33791 63448161
Haemodynamic instability 69.06 29.56 29 7041 9161 63472791
Delayed recovery from anaesthesia 67.75 29.56 16 7054 755 63481197
Myoclonus 65.43 29.56 33 7037 15835 63466117
Rash maculo-papular 65.41 29.56 42 7028 31854 63450098
Ventricular fibrillation 65.05 29.56 30 7040 11837 63470115
Stress cardiomyopathy 64.98 29.56 28 7042 9422 63472530
Hepatorenal failure 64.12 29.56 15 7055 679 63481273
Toxic epidermal necrolysis 63.73 29.56 38 7032 25296 63456656
Peripheral nerve injury 59.29 29.56 13 7057 438 63481514
Anticholinergic syndrome 58.20 29.56 18 7052 2364 63479588
Spinal epidural haemorrhage 57.07 29.56 10 7060 100 63481852
Suspected product quality issue 55.96 29.56 11 7059 214 63481738
Hypocapnia 55.48 29.56 12 7058 379 63481573
Serotonin syndrome 52.06 29.56 35 7035 28647 63453305
Unwanted awareness during anaesthesia 51.50 29.56 11 7059 327 63481625
Carcinoid crisis 48.26 29.56 10 7060 256 63481696
Oxygen saturation decreased 47.80 29.56 54 7016 88531 63393421
Erythema 46.91 29.56 76 6994 175675 63306277
Vasoplegia syndrome 46.46 29.56 14 7056 1685 63480267
Patent ductus arteriosus 44.38 29.56 17 7053 4233 63477719
Metabolic acidosis 44.02 29.56 38 7032 45031 63436921
Spinal epidural haematoma 42.86 29.56 12 7058 1115 63480837
Stevens-Johnson syndrome 41.85 29.56 29 7041 24921 63457031
Myoglobin blood increased 40.25 29.56 12 7058 1393 63480559
Cholestasis 39.75 29.56 30 7040 29404 63452548
Hyperlactacidaemia 39.35 29.56 14 7056 2835 63479117
Paralysis 39.09 29.56 20 7050 9880 63472072
Dermatitis bullous 38.94 29.56 19 7051 8489 63473463
Mydriasis 38.28 29.56 21 7049 11935 63470017
Diarrhoea 38.27 29.56 16 7054 715350 62766602
Uterine hypotonus 37.20 29.56 7 7063 107 63481845
Epidural haemorrhage 36.45 29.56 7 7063 120 63481832
Anaesthetic complication 36.31 29.56 12 7058 1948 63480004
Postpartum haemorrhage 36.19 29.56 12 7058 1969 63479983
Torsade de pointes 36.12 29.56 21 7049 13330 63468622
Generalised tonic-clonic seizure 35.74 29.56 28 7042 28988 63452964
Sinus tachycardia 35.60 29.56 26 7044 24242 63457710
Cauda equina syndrome 35.07 29.56 10 7060 992 63480960
Hyperthermia 34.72 29.56 18 7052 9138 63472814
Post procedural stroke 34.71 29.56 6 7064 55 63481897
Altered state of consciousness 34.70 29.56 26 7044 25204 63456748
Acute pulmonary oedema 33.72 29.56 17 7053 8141 63473811
Posterior reversible encephalopathy syndrome 33.48 29.56 22 7048 17323 63464629
Foetal exposure during pregnancy 33.36 29.56 28 7042 31934 63450018
Reversal of opiate activity 32.41 29.56 4 7066 0 63481952
Premature baby 32.21 29.56 23 7047 20712 63461240
Foetal growth restriction 31.99 29.56 16 7054 7537 63474415
Suspected product contamination 31.56 29.56 5 7065 25 63481927
Angioedema 30.68 29.56 32 7038 47933 63434019
Cardiogenic shock 30.43 29.56 21 7049 17911 63464041
Haemodilution 30.04 29.56 6 7064 127 63481825
Foetal heart rate abnormal 29.88 29.56 8 7062 629 63481323

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 1151.54 30.58 300 5101 15641 34935889
Bronchospasm 190.35 30.58 69 5332 10662 34940868
Hyperthermia malignant 180.77 30.58 46 5355 2131 34949399
Hypotension 136.73 30.58 169 5232 221480 34730050
Anaphylactic reaction 133.69 30.58 75 5326 32226 34919304
Hypertransaminasaemia 114.31 30.58 40 5361 5566 34945964
Toxic epidermal necrolysis 111.11 30.58 58 5343 21588 34929942
Rash maculo-papular 109.45 30.58 63 5338 28388 34923142
Tachycardia 101.02 30.58 92 5309 84680 34866850
Eosinophilia 84.98 30.58 52 5349 26170 34925360
Circulatory collapse 84.67 30.58 48 5353 20990 34930540
Drug reaction with eosinophilia and systemic symptoms 83.52 30.58 56 5345 32956 34918574
Cholestasis 71.25 30.58 47 5354 26901 34924629
Haemodynamic instability 71.20 30.58 33 5368 9490 34942040
Erythema 64.78 30.58 74 5327 88706 34862824
Shock 61.09 30.58 41 5360 24138 34927392
Rhabdomyolysis 60.48 30.58 63 5338 68100 34883430
Type I hypersensitivity 58.18 30.58 17 5384 1322 34950208
Septic shock 56.00 30.58 62 5339 71772 34879758
Hepatic cytolysis 52.77 30.58 31 5370 14465 34937065
Injury 52.06 30.58 35 5366 20652 34930878
Allergy test negative 52.06 30.58 10 5391 121 34951409
Rash morbilliform 47.86 30.58 18 5383 3069 34948461
Delayed recovery from anaesthesia 47.65 30.58 13 5388 788 34950742
Cardiac arrest 47.52 30.58 66 5335 96093 34855437
Hepatorenal failure 47.16 30.58 12 5389 554 34950976
Victim of crime 46.55 30.58 11 5390 372 34951158
Anaphylactoid shock 46.41 30.58 11 5390 377 34951153
Multiple organ dysfunction syndrome 44.65 30.58 57 5344 76509 34875021
Stress cardiomyopathy 43.14 30.58 15 5386 2044 34949486
Hepatocellular injury 42.95 30.58 32 5369 22179 34929351
Patent ductus arteriosus 39.42 30.58 16 5385 3338 34948192
Mixed liver injury 38.27 30.58 15 5386 2858 34948672
Suspected product quality issue 38.12 30.58 8 5393 155 34951375
Suspected product contamination 37.39 30.58 7 5394 73 34951457
Infantile apnoea 36.52 30.58 11 5390 950 34950580
Post procedural haemorrhage 36.28 30.58 20 5381 8269 34943261
Coma 34.82 30.58 39 5362 45639 34905891
Fear 34.48 30.58 21 5380 10455 34941075
Bradycardia 33.16 30.58 49 5352 75369 34876161
Fibrinolysis increased 32.76 30.58 5 5396 12 34951518
Symmetrical drug-related intertriginous and flexural exanthema 31.88 30.58 8 5393 349 34951181
Acute generalised exanthematous pustulosis 31.46 30.58 17 5384 6759 34944771
Agitation neonatal 30.96 30.58 10 5391 1086 34950444
Diarrhoea 30.76 30.58 11 5390 389901 34561629
Anaesthetic complication 30.75 30.58 10 5391 1110 34950420

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 2865.51 27.40 723 10912 35273 79697480
Bronchospasm 446.77 27.40 159 11476 24700 79708053
Anaphylactic reaction 361.61 27.40 196 11439 83547 79649206
Hypotension 318.04 27.40 354 11281 439963 79292790
Tachycardia 199.59 27.40 182 11453 177586 79555167
Hyperthermia malignant 193.63 27.40 51 11584 2866 79729887
Circulatory collapse 175.89 27.40 93 11542 37575 79695178
Cardiac arrest 169.71 27.40 164 11471 171932 79560821
Maternal exposure during delivery 167.62 27.40 39 11596 1307 79731446
Type I hypersensitivity 155.54 27.40 47 11588 4351 79728402
Toxic epidermal necrolysis 153.26 27.40 90 11545 44491 79688262
Rash maculo-papular 148.91 27.40 96 11539 55982 79676771
Drug reaction with eosinophilia and systemic symptoms 148.84 27.40 101 11534 64143 79668610
Anaphylactoid shock 142.94 27.40 31 11604 750 79732003
Eosinophilia 138.90 27.40 85 11550 45260 79687493
Allergy test negative 137.35 27.40 26 11609 308 79732445
Shock 136.90 27.40 83 11552 43465 79689288
Acute generalised exanthematous pustulosis 120.36 27.40 56 11579 17198 79715555
Mixed liver injury 111.94 27.40 42 11593 7536 79725217
Delayed recovery from anaesthesia 109.83 27.40 29 11606 1644 79731109
Hypertransaminasaemia 109.76 27.40 47 11588 11877 79720876
Hepatorenal failure 107.41 27.40 27 11608 1258 79731495
Erythema 106.13 27.40 146 11489 223144 79509609
Haemodynamic instability 104.70 27.40 51 11584 17331 79715422
Cholestasis 104.47 27.40 75 11560 52034 79680719
Hepatocellular injury 103.52 27.40 72 11563 47521 79685232
Fatigue 100.26 27.40 10 11625 929717 78803036
Stress cardiomyopathy 99.45 27.40 43 11592 11123 79721630
Multiple organ dysfunction syndrome 98.95 27.40 104 11531 120142 79612611
Suspected product quality issue 95.41 27.40 19 11616 298 79732455
Cardio-respiratory arrest 82.47 27.40 90 11545 108420 79624333
Respiratory depression 80.02 27.40 50 11585 27580 79705173
Bradycardia 77.28 27.40 97 11538 135460 79597293
Oliguria 72.51 27.40 39 11596 16270 79716483
Suspected product contamination 68.10 27.40 12 11623 92 79732661
Septic shock 67.02 27.40 86 11549 122715 79610038
Rash morbilliform 65.84 27.40 27 11608 6123 79726630
Rhabdomyolysis 65.57 27.40 78 11557 103053 79629700
Anaesthetic complication 61.73 27.40 21 11614 2838 79729915
Diarrhoea 59.80 27.40 27 11608 880462 78852291
Carcinoid crisis 59.05 27.40 14 11621 509 79732244
Hepatic cytolysis 56.51 27.40 40 11595 27111 79705642
Myoclonus 55.84 27.40 40 11595 27620 79705133
Acute pulmonary oedema 54.92 27.40 31 11604 14199 79718554
Dizziness 53.25 27.40 7 11628 526434 79206319
Torsade de pointes 51.06 27.40 33 11602 19279 79713474
Peripheral nerve injury 49.86 27.40 13 11622 701 79732052
Vasoplegia syndrome 49.57 27.40 19 11616 3611 79729142
Dermatitis bullous 49.55 27.40 29 11606 14216 79718537
Unwanted awareness during anaesthesia 48.93 27.40 11 11624 315 79732438
Symmetrical drug-related intertriginous and flexural exanthema 47.08 27.40 13 11622 873 79731880
Ventricular fibrillation 46.47 27.40 38 11597 31888 79700865
Hypocapnia 46.32 27.40 12 11623 631 79732122
Anticholinergic syndrome 46.10 27.40 18 11617 3593 79729160
Headache 45.98 27.40 19 11616 653753 79079000
Spinal epidural haemorrhage 44.96 27.40 9 11626 145 79732608
Exposure during pregnancy 44.77 27.40 64 11571 101068 79631685
Victim of crime 44.52 27.40 11 11624 477 79732276
Fibrinolysis increased 44.20 27.40 7 11628 25 79732728
Coma 43.53 27.40 63 11572 100586 79632167
Altered state of consciousness 43.51 27.40 42 11593 43780 79688973
Neuromuscular block prolonged 40.72 27.40 12 11623 1018 79731735
Fall 39.77 27.40 11 11624 487618 79245135
Oxygen saturation decreased 39.55 27.40 69 11566 128978 79603775
Respiratory acidosis 39.48 27.40 23 11612 11177 79721576
Ventricular tachycardia 39.40 27.40 39 11596 41896 79690857
Nervous system disorder 39.15 27.40 32 11603 26824 79705929
Hyperlactacidaemia 38.51 27.40 18 11617 5577 79727176
Fear 38.09 27.40 29 11606 21957 79710796
Arthralgia 38.01 27.40 18 11617 571785 79160968
Acute respiratory distress syndrome 37.78 27.40 39 11596 44028 79688725
Cardiogenic shock 37.58 27.40 38 11597 41876 79690877
Uterine hypotonus 36.97 27.40 7 11628 83 79732670
Spinal epidural haematoma 36.82 27.40 12 11623 1420 79731333
Anaesthetic complication neurological 36.77 27.40 10 11625 634 79732119
Postpartum haemorrhage 35.55 27.40 12 11623 1583 79731170
Tonic clonic movements 35.08 27.40 13 11622 2251 79730502
Malaise 34.79 27.40 14 11621 489855 79242898
Metabolic acidosis 33.29 27.40 50 11585 82479 79650274
Renal injury 33.07 27.40 24 11611 16903 79715850
Cauda equina syndrome 33.04 27.40 11 11624 1392 79731361
Anaphylactoid reaction 32.91 27.40 16 11619 5406 79727347
Haemodilution 32.86 27.40 7 11628 155 79732598
Device issue 32.76 27.40 29 11606 27079 79705674
Mydriasis 32.17 27.40 24 11611 17619 79715134
Urticaria 31.82 27.40 78 11557 185123 79547630
Foetal heart rate abnormal 31.75 27.40 8 11627 376 79732377
Hyperdynamic left ventricle 31.37 27.40 8 11627 395 79732358
Leukocytosis 31.17 27.40 35 11600 43420 79689333
Weight decreased 30.90 27.40 7 11628 355191 79377562
Epidural haemorrhage 30.54 27.40 7 11628 219 79732534
Weight increased 29.73 27.40 3 11632 277383 79455370
Post procedural stroke 29.35 27.40 6 11629 108 79732645
Angioedema 29.16 27.40 45 11590 75990 79656763
Cough 28.56 27.40 9 11626 366780 79365973
Nausea 28.40 27.40 61 11574 957135 78775618
Post procedural haemorrhage 28.02 27.40 20 11615 13724 79719029
Hypercapnia 27.97 27.40 17 11618 8918 79723835
Third stage postpartum haemorrhage 27.67 27.40 4 11631 6 79732747
Myoglobin blood increased 27.61 27.40 12 11623 3139 79729614

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N01AH03 NERVOUS SYSTEM
ANESTHETICS
ANESTHETICS, GENERAL
Opioid anesthetics
CHEBI has role CHEBI:35482 narcotic analgesic
CHEBI has role CHEBI:38877 intravenous anesthetics
CHEBI has role CHEBI:55322 mu-opioid agonists
CHEBI has role CHEBI:60807 anaesthestic adjuvant
FDA MoA N0000175684 Full Opioid Agonists
FDA EPC N0000175690 Opioid Agonist
MeSH PA D000759 Adjuvants, Anesthesia
MeSH PA D000700 Analgesics
MeSH PA D000701 Analgesics, Opioid
MeSH PA D000777 Anesthetics
MeSH PA D018686 Anesthetics, Intravenous
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D009294 Narcotics
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
General anesthesia indication 50697003
Postoperative pain indication 213299007
Asthenia contraindication 13791008
Chronic disease of respiratory system contraindication 17097001
Decreased cardiac function contraindication 43650005
Bradycardia contraindication 48867003
Injury of head contraindication 82271004
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.37 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 0.03MG BASE DSUVIA VERTICAL PHARMS N209128 Nov. 2, 2018 RX TABLET SUBLINGUAL 10245228 Jan. 5, 2027 TREATMENT OF ACUTE PAIN
EQ 0.03MG BASE DSUVIA VERTICAL PHARMS N209128 Nov. 2, 2018 RX TABLET SUBLINGUAL 10507180 Jan. 5, 2027 TREATMENT OF ACUTE PAIN
EQ 0.03MG BASE DSUVIA VERTICAL PHARMS N209128 Nov. 2, 2018 RX TABLET SUBLINGUAL 8226978 Jan. 5, 2027 TREATMENT OF ACUTE PAIN
EQ 0.03MG BASE DSUVIA VERTICAL PHARMS N209128 Nov. 2, 2018 RX TABLET SUBLINGUAL 8535714 Jan. 5, 2027 TREATMENT OF ACUTE PAIN
EQ 0.03MG BASE DSUVIA VERTICAL PHARMS N209128 Nov. 2, 2018 RX TABLET SUBLINGUAL 8778393 Jan. 5, 2027 TREATMENT OF ACUTE PAIN
EQ 0.03MG BASE DSUVIA VERTICAL PHARMS N209128 Nov. 2, 2018 RX TABLET SUBLINGUAL 8778394 Jan. 5, 2027 TREATMENT OF ACUTE PAIN
EQ 0.03MG BASE DSUVIA VERTICAL PHARMS N209128 Nov. 2, 2018 RX TABLET SUBLINGUAL 8865211 Jan. 5, 2027 TREATMENT OF ACUTE PAIN
EQ 0.03MG BASE DSUVIA VERTICAL PHARMS N209128 Nov. 2, 2018 RX TABLET SUBLINGUAL 9320710 Jan. 5, 2027 TREATMENT OF ACUTE PAIN
EQ 0.03MG BASE DSUVIA VERTICAL PHARMS N209128 Nov. 2, 2018 RX TABLET SUBLINGUAL 8202535 Oct. 22, 2030 TREATMENT OF ACUTE PAIN
EQ 0.03MG BASE DSUVIA VERTICAL PHARMS N209128 Nov. 2, 2018 RX TABLET SUBLINGUAL 8865743 Oct. 22, 2030 TREATMENT OF ACUTE PAIN

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Mu-type opioid receptor GPCR AGONIST EC50 8.13 WOMBAT-PK CHEMBL
Kappa-type opioid receptor GPCR EC50 6.70 WOMBAT-PK
Delta-type opioid receptor GPCR Ki 7.30 PDSP
Solute carrier family 22 member 1 Transporter IC50 4.71 CHEMBL
Mu-type opioid receptor GPCR Ki 9.66 CHEMBL
Sigma non-opioid intracellular receptor 1 Membrane other IC50 5.68 CHEMBL
Opioid receptor GPCR Ki 10.70 CHEMBL

External reference:

IDSource
4019936 VUID
N0000148021 NUI
D00845 KEGG_DRUG
60561-17-3 SECONDARY_CAS_RN
4019269 VANDF
4019936 VANDF
C0143993 UMLSCUI
CHEBI:9316 CHEBI
CHEMBL658 ChEMBL_ID
DB00708 DRUGBANK_ID
CHEMBL1201163 ChEMBL_ID
D017409 MESH_DESCRIPTOR_UI
41693 PUBCHEM_CID
3534 IUPHAR_LIGAND_ID
4048 INN_ID
AFE2YW0IIZ UNII
56795 RXNORM
10199 MMSL
32203 MMSL
5519 MMSL
d00378 MMSL
001570 NDDF
004630 NDDF
370275005 SNOMEDCT_US
37527009 SNOMEDCT_US
49998007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Sufentanil Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0409-3382 INJECTION, SOLUTION 50 ug EPIDURAL ANDA 33 sections
Sufentanil Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0409-3382 INJECTION, SOLUTION 50 ug EPIDURAL ANDA 33 sections
Sufentanil Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0641-6110 INJECTION 0.05 mg EPIDURAL ANDA 27 sections
Sufentanil Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0641-6111 INJECTION 0.05 mg EPIDURAL ANDA 27 sections
Sufentanil Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0641-6112 INJECTION 0.05 mg EPIDURAL ANDA 27 sections
Sufentanil Citrate HUMAN PRESCRIPTION DRUG LABEL 1 17478-050 INJECTION 50 ug INTRAVENOUS NDA 29 sections
Sufentanil Citrate HUMAN PRESCRIPTION DRUG LABEL 1 17478-050 INJECTION 50 ug INTRAVENOUS NDA 29 sections
Dsuvia Human Prescription Drug Label 1 61621-430 TABLET 30 ug SUBLINGUAL NDA 30 sections